Seabury Jamison, Weinstein Jennifer, Varma Anika, Rosero Spencer James, Engebrecht Charlotte, Arky Abigail, Zizzi Christine, Dilek Nuran, Mathewson Abigail, Salem-Spencer Susan, Santos Elizabeth J, Heatwole Chad Rydel
University of Rochester School of Medicine and Dentistry (JS, AV); Center for Health and Technology (CHeT) (JS, JW, AV, SJR, CE, AA, CZ, CRH), University of Rochester; University of Utah Spencer Fox Eccles School of Medicine (SJR); Des Moines University College of Osteopathic Medicine (AA); Department of Biostatistics and Neurology (ND), University of Rochester; Alzheimer's Disease Care, Research and Education Program (AD-CARE) (AM, SS-S, EJS), University of Rochester; and Department of Neurology (CRH), University of Rochester.
Neurol Clin Pract. 2025 Feb;15(1):e200418. doi: 10.1212/CPJ.0000000000200418. Epub 2024 Dec 6.
In preparation for future clinical trials involving individuals with Alzheimer disease (AD), mild cognitive impairment (MCI), and dementia, it is important to ascertain the widespread impact of symptoms from the direct perspectives of patients and caregivers. In this study, we performed cross-sectional surveys using large-scale patient and caregiver data to identify the prevalence and average impact of symptoms and symptomatic themes experienced by adults with AD, MCI, and dementia. Subsequent analyses were used to determine which demographic and disease-specific factors are associated with more severe disease.
Fifteen adults with AD (6), MCI (8), and dementia (1) and 15 caregivers of adults with AD (7), MCI (6), and dementia (2) participated in qualitative interviews providing 1,166 and 1,097 unique quotes pertaining to symptom burden. Using open-ended questions from a comprehensive interview guide, participants were asked to identify the symptoms of AD that have the greatest effect on their lives or the lives of the individual for whom they provide care. A cross-sectional survey was then implemented inquiring about the potential symptoms of importance identified during preliminary qualitative interviews. Four-hundred thirty-three individuals (patients and caregivers) participated in the cross-sectional survey, providing more than 35,000 symptom rating responses. Subsequent analyses were conducted to determine how demographic and disease-specific characteristics correlate with symptomatic theme prevalence.
The most frequent symptomatic themes reported by individuals with AD, MCI, and dementia in the cross-sectional survey were memory problems (99.0%), problems thinking (90.3%), and communication difficulties (80.4%). Patients identified decreased satisfaction in social situations (1.45), fatigue (1.45), and memory problems (1.41) as the most impactful symptomatic themes (range 0-4). Patient-reported symptomatic theme prevalence was strongly associated with the Modified Rankin Scale (mRS) for neurologic disability.
Individuals with AD, MCI, and dementia experience a variety of symptoms that significantly affect their daily lives. These symptoms, many underrecognized, are of variable importance to individuals with these diseases and may inform potential targets for future therapeutic intervention as well as facilitate the development and validation of disease-specific outcome measures.
为未来涉及阿尔茨海默病(AD)、轻度认知障碍(MCI)和痴呆症患者的临床试验做准备,从患者和护理人员的直接角度确定症状的广泛影响非常重要。在本研究中,我们使用大规模患者和护理人员数据进行横断面调查,以确定AD、MCI和痴呆症成人患者经历的症状、症状主题的患病率及平均影响。后续分析用于确定哪些人口统计学和疾病特异性因素与更严重的疾病相关。
15名患有AD(6名)、MCI(8名)和痴呆症(1名)的成人以及15名患有AD(7名)、MCI(6名)和痴呆症(2名)的成人的护理人员参与了定性访谈,提供了1166条和1097条与症状负担相关的独特引述。使用综合访谈指南中的开放式问题,要求参与者识别对他们自己的生活或他们所照顾的人的生活影响最大的AD症状。然后进行横断面调查,询问在初步定性访谈中确定的潜在重要症状。433名个体(患者和护理人员)参与了横断面调查,提供了超过35000条症状评分回复。随后进行分析,以确定人口统计学和疾病特异性特征与症状主题患病率之间的相关性。
在横断面调查中,AD、MCI和痴呆症患者报告的最常见症状主题是记忆问题(99.0%)、思维问题(90.3%)和沟通困难(80.4%)。患者将社交场合满意度下降(1.45)、疲劳(1.45)和记忆问题(1.41)确定为最具影响力的症状主题(范围0 - 4)。患者报告的症状主题患病率与神经功能残疾改良Rankin量表(mRS)密切相关。
AD、MCI和痴呆症患者会经历多种严重影响其日常生活的症状。这些症状,其中许多未得到充分认识,对这些疾病患者的重要性各不相同,可能为未来治疗干预的潜在靶点提供信息,并有助于开发和验证疾病特异性结局指标。